Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, Utah.
Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah.
Cancer Epidemiol Biomarkers Prev. 2022 Nov 2;31(11):2038-2045. doi: 10.1158/1055-9965.EPI-22-0587.
The degree to which uterine cancer metastatic to the ovary is misdiagnosed as synchronous stage I uterine and ovarian cancers is unclear. We sought to determine whether patients with synchronous cancers had mortality patterns similar to either stage IIIA uterine, stage I uterine, or stage I ovarian cancers alone.
The Surveillance, Epidemiology, and End Results database was used to compare mortality of patients with synchronous stage I uterine and stage I ovarian cancers versus those with stage IIIA uterine, stage I uterine, or stage I ovarian cancers alone. We calculated age-adjusted mortality hazard ratios (HR) and 95% confidence intervals (CI) accounting for calendar year and grade, adjuvant treatment, grade 1 endometrioid cancers, grade 3 endometrioid cancers, and stage IA cancers.
Among the 9,321 patients, we observed lower age-adjusted mortality in patients with stage I synchronous cancers (n = 937) compared to those with stage IIIA uterine (n = 531; HR, 0.45 95% CI, 0.35-0.58), stage I uterine (n = 6,919; HR, 0.74; 95% CI, 0.60-0.91), and stage I ovarian cancers (n = 934; HR, 0.52; 95% CI, 0.41-0.67). Results were similar after taking into account diagnosis year and grade, and limiting to those receiving adjuvant therapy, grade 1 or grade 3 endometrioid cancers, or stage IA cancers.
We observed lower mortality for synchronous stage I uterine and ovarian cancers, which was not explained by younger age, earlier stage, lower grade, histology type, or adjuvant therapy.
The possible misdiagnosis associated with clinicopathologic of synchronous uterine and ovarian cancers does not appear to worsen survival on a population level.
子宫癌转移至卵巢被误诊为同期 I 期子宫和卵巢癌的程度尚不清楚。我们试图确定同期癌症患者的死亡率模式是否与单独的 IIIA 期子宫癌、I 期子宫癌或 I 期卵巢癌相似。
使用监测、流行病学和最终结果数据库比较同期 I 期子宫和 I 期卵巢癌患者与单独 IIIA 期子宫、I 期子宫或 I 期卵巢癌患者的死亡率。我们计算了年龄调整后的死亡率风险比(HR)和 95%置信区间(CI),考虑了日历年度和分级、辅助治疗、I 级子宫内膜样癌、III 级子宫内膜样癌和 IA 期癌症。
在 9321 名患者中,我们观察到同期 I 期癌症患者(n=937)的年龄调整死亡率低于 IIIA 期子宫癌患者(n=531;HR,0.45;95%CI,0.35-0.58)、I 期子宫癌患者(n=6919;HR,0.74;95%CI,0.60-0.91)和 I 期卵巢癌患者(n=934;HR,0.52;95%CI,0.41-0.67)。在考虑诊断年份和分级、限制接受辅助治疗、I 级或 III 级子宫内膜样癌或 IA 期癌症的患者后,结果仍然相似。
我们观察到同期 I 期子宫和卵巢癌的死亡率较低,这不能用年龄较小、分期较早、分级较低、组织学类型或辅助治疗来解释。
与同期子宫和卵巢癌的临床病理相关的可能误诊似乎不会降低人群水平的生存率。